A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-sensitive recurrent ovarian cancer.

@article{Penson2011API,
  title={A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-sensitive recurrent ovarian cancer.},
  author={Richard T. Penson and Christin Whalen and Brian Lasonde and Carolyn N. Krasner and Panagiotis Konstantinopoulos and T E Stallings and Christopher R. Bradley and Michael J. Birrer and Ursula A. Matulonis},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 15_suppl},
  pages={5004}
}
5004 Background: GC is an established chemotherapy combination for patients with platinum-sensitive recurrent ovarian cancer, with an associated overall response rate (ORR) of 47.2% (Pfisterer et al. JCO 2006; 24:4699). Addition of iniparib (BSI-201), an anticancer agent with poly(ADP-ribose) polymerase inhibitory activity, to GC potentiates the activity of GC alone, with low incremental toxicities, in patients with metastatic triple-negative breast cancer (O'Shaughnessy et al. NEJM 2011). This… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

Similar Papers

Loading similar papers…